News & Updates
Filter by Specialty:
Thyroid hormone sensitivity tied to advanced liver fibrosis in NAFLD
In euthyroid patients with nonalcoholic fatty liver disease (NAFLD), higher values of thyroid hormone sensitivity markers, such as the thyroid-stimulating hormone (TSH) index (TSHI) and thyroid feedback quantile-based index (TFQI), appear to aggravate the risk of advanced fibrosis, a recent study has found.
Thyroid hormone sensitivity tied to advanced liver fibrosis in NAFLD
30 Jul 2022
Low free sugar diet improves clinical biomarkers in NAFLD patients
In overweight/obese patients with nonalcoholic fatty liver disease (NAFLD), a low free sugar diet may result in decreased hepatic steatosis and fibrosis, as well as better glycaemic indices and lower concentrations of biomarkers of inflammation, triglycerides (TG), and total cholesterol (TC) levels, suggests a recent study.
Low free sugar diet improves clinical biomarkers in NAFLD patients
30 Jul 2022
Growth hormone reduces liver fat, fibro-inflammation in obese/overweight adults with NAFLD
In adults with overweight/obesity and nonalcoholic fatty liver disease (NAFLD), daily administration of growth hormone (GH) reduced hepatic steatosis and improved markers of hepatic inflammation and fibrosis, a study has shown.
Growth hormone reduces liver fat, fibro-inflammation in obese/overweight adults with NAFLD
27 Jul 2022
Sugar-sweetened drinks tied to increased liver cancer risk?
A high intake of sugar-sweetened beverages (SSBs) may be linked to an increased risk of liver cancer, according to an observational study on postmenopausal women presented at Nutrition 2022.
Sugar-sweetened drinks tied to increased liver cancer risk?
24 Jul 2022
20-µg hep B vaccine can prevent vertical transmission
Using a 20-µg dose to vaccinate children born to mothers with detectable levels of hepatitis B virus surface antigen (HBsAg) appears to avert vertical transmission, reports a recent China study.
20-µg hep B vaccine can prevent vertical transmission
23 Jul 2022
HCV treatment helps prevent cirrhosis, death in persons who inject drugs
People who inject drugs (PWID) and are receiving treatment for hepatitis C virus (HCV) show a substantial decline in liver disease and mortality, according to a study.
HCV treatment helps prevent cirrhosis, death in persons who inject drugs
22 Jul 2022
Real-world studies demonstrate TAF efficacy and safety in chronic hep B
Treatment with tenofovir alafenamide (TAF) results in similar virological response compared with tenofovir disoproxil fumarate (TDF) in treatment-naïve patients with chronic hepatitis B (CHB), according to a real-world study from Korea presented at ILC 2022.
Real-world studies demonstrate TAF efficacy and safety in chronic hep B
20 Jul 2022
Unexplained hepatitis outbreak in kids: Are COVID-19, adenovirus the triggers?
Cases of acute, severe hepatitis of unknown aetiology in young children have increased recently and investigations are underway, says an expert during a media briefing at ILC 2022.
Unexplained hepatitis outbreak in kids: Are COVID-19, adenovirus the triggers?
19 Jul 2022
Chronic hepatitis C tied to cardiovascular events in T2DM
In patients with type 2 diabetes mellitus (T2DM), chronic hepatitis C and fatty liver appear to worsen the risk of cardiovascular events, a recent Taiwan study has found.
Chronic hepatitis C tied to cardiovascular events in T2DM
19 Jul 2022
Resmetirom demos potential in NASH
Safety analysis of the phase III MAESTRO-NAFLD-1 trial presented at ILC 2022 demonstrated the potential of resmetirom as a treatment for patients with non-alcoholic steatohepatitis (NASH) who have liver fibrosis.